In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Morepen Laboratories has informed that the Board of Directors at their meeting held today, Monday, 9th May, 2022 (commenced at 10:30 AM and concluded at 11:30 AM), approved the allotment of 1,14,65,201, 0.01%, Compulsorily Convertible Preference Shares ('CCPS') of Rs 100 each, convertible into 2,13,42,505 Equity Shares of Rs 2 each, at an issue price of Rs 53.72 per Equity Share, within a maximum period of 18 months in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: